

DAFTAR PUSTAKA

- [1] F. Forouzanfar, B. S. F. Bazzaz, dan H. Hosseinzadeh, "Black cumin (*Nigella sativa*) and its constituent (thymoquinone): A review on antimicrobial effects," *Iran. J. Basic Med. Sci.*, vol. 17, no. 12, hal. 929, 2014.
- [2] S. Rooney dan M. F. Ryan, "Effects of alpha-hederin and thymoquinone, constituents of *Nigella sativa*, on human cancer cell lines," *Anticancer Res.*, vol. 25, no. 3B, hal. 2199–2204, 2005.
- [3] M. Ismail, G. Al-Naqeep, dan K. W. Chan, "Nigella sativa thymoquinone-rich fraction greatly improves plasma antioxidant capacity and expression of antioxidant genes in hypercholesterolemic rats," *Free Radic. Biol. Med.*, vol. 48, no. 5, hal. 664–672, Mar 2010.
- [4] M. El Gazzar, R. El Mezayen, J. C. Marecki, M. R. Nicolls, A. Canastar, dan S. C. Dreskin, "Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation," *Int. Immunopharmacol.*, vol. 6, no. 7, hal. 1135–1142, Jul 2006.
- [5] H. Gali-Muhtasib, A. Roessner, dan R. Schneider-Stock, "Thymoquinone: A promising anti-cancer drug from natural sources," *Int. J. Biochem. Cell Biol.*, vol. 38, no. 8, hal. 1249–1253, Jan 2006.
- [6] F. Odeh, S. I. Ismail, R. Abu-Dahab, I. S. Mahmoud, dan A. Al Bawab, "Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer," *Drug Deliv.*, vol. 19, no. 8, hal. 371–377, Nov 2012.
- [7] M. AbuKhader, "Thymoquinone in the clinical treatment of cancer: Fact or fiction?," *Pharmacogn. Rev.*, vol. 7, no. 14, hal. 117, 2013.
- [8] A. M. Dar dan S. Mir, "Molecular Docking: Approaches, Types, Applications and Basic Challenges," *J. Anal. Bioanal. Tech.*, vol. 8, no. 2, 2017.

- [9] M. M. Hossain, P. K. Roy, A. T. M. J. Mosnaz, dan S. K. Shakil, “Structural analysis and molecular docking of potential ligands with chorismate synthase of *Listeria monocytogenes*: A novel antibacterial drug target,” *Indian J. Biochem. Biophys.*, vol. 52, hal. 45–59, 2015.
- [10] D. P. de Sousa, *Bioactive Essential Oils and Cancer*. London: Springer International Publishing Switzerland, 2015.
- [11] Y. N. Antonenko *et al.*, “Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: Synthesis and in vitro studies,” *Biochem. Mosc.*, vol. 73, no. 12, hal. 1273–1287, Des 2008.
- [12] I. I. Severina *et al.*, “In search of novel highly active mitochondria-targeted antioxidants: Thymoquinone and its cationic derivatives,” *FEBS Lett.*, vol. 587, no. 13, hal. 2018–2024, Jun 2013.
- [13] M. F. Ullah, *Critical Dietary Factors in Cancer Chemoprevention*. Springer International Publishing Switzerland, 2016.
- [14] Sigma Aldrich, “Material Safety Data Sheet Thymoquinone.” Tersedia pada: <http://sigma-aldrich.com>. [Diakses: 21-Jul-2017].
- [15] I. Nallamuthu, A. Parthasarathi, dan F. Khanum, “Thymoquinone-loaded PLGA nanoparticles: antioxidant and anti-microbial properties.”, 2013.
- [16] S. M. Ulfa, S. Sholikhah, dan E. P. Utomo, “Synthesis of Thymoquinone derivatives and its activity analysis: In-silico approach,” 2017, hal. 20102.
- [17] J. D. Robert dan M. C. Caserio, *Basic Principles of Organic Chemistry*, 2 ed. Menlo Park: W. A. Benjamin, Inc., 1977.
- [18] J. McMurry, *Organic Chemistry*, 7 ed. Belmont: Thomson Learning, Inc., 2008.

- [19] T. Soderberg, *Organic Chemistry with a Biological Emphasis*. Morris: University of Minnesota, 2014.
- [20] W. Brown, C. Foote, B. Iverson, dan E. Anslyn, *Organic Chemistry*, 5 ed. Cengage Learning, 2010.
- [21] J. Sherma dan B. Fried, *Handbook of Thin-Layer Chromatography*, 3 ed., vol. 89. New York: Marcel Dekker, Inc.
- [22] J. C. Touchstone, *Practice of Thin Layer Chromatography*, Third. New York: John Willey and Sons, Inc., 1992.
- [23] J. Clark, "Column Chromatography," 2007. .
- [24] P.-C. Hsiung, "Column Chromatography Theory," 2010. [Daring]. Tersedia pada: www.utsch.utoronto.ca.
- [25] N. E. Jacobsen, *NMR Spectroscopy Explained : Simplified Theory, Applications and Examples for Organic Chemistry and Structural Biology*. New Jersey: John Willey and Sons, Inc., 2007.
- [26] J. Keeler, *Understanding NMR Spectroscopy*, 2 ed. Cambridge: John Willey and Sons, Inc.
- [27] R. J. Anderson, D. J. Bendell, dan P. W. Groundwater, *Organic Spectroscopic Analysis*. Cambridge: The Royal Society of Chemistry, 2004.
- [28] S. Shityakov dan C. Foerster, "In silico structure-based screening of versatile P-glycoprotein inhibitors using polynomial empirical scoring functions," *Adv. Appl. Bioinforma. Chem.*, hal. 1, Mar 2014.
- [29] D. J. Baker, J. A. Timmons, dan P. L. Greenhaff, "Glycogen phosphorylase inhibition in type 2 diabetes therapy," *Diabetes*, vol. 54, no. 8, hal. 2453–2459, 2005.
- [30] M. WH *et al.*, "Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo," *Proc Nall Acad Sci U A*, vol. 95, hal. 1776–1781.
- [31] I. Kaljurand, "UV-Vis spectra of neutral bases and their protonated conjugate cationic acids in acetonitrile," 2001. [Daring]. Tersedia pada: tera.chem.ut.ee.

- [32] A. Andrés *et al.*, “Setup and validation of shake-flask procedures for the determination of partition coefficients (logD) from low drug amounts,” *Eur. J. Pharm. Sci.*, vol. 76, hal. 181–191, Agu 2015.
- [33] N. Musyahadah, N. Hariani, dan M. Hendra, “Uji Efektifitas Ekstrak Daun Tigaron (*Crateva religiosa* G. Forst.) Terhadap Mortalitas Ulat Grayak (*Spodoptera litura* F.)(Lepidoptera: Noctuidae) di Laboratorium,” in *Prosiding Seminar Sains dan Teknologi FMIPA Unmul*, 2015, vol. 1, hal. 1–7.
- [34] K. Moscou dan K. R., *Pharmacology for Pharmacy Technician*. Elsevier inc., 2013.